22.7 USD
-0.26 (-1.13%)
22.6 USD
-0.1 (-0.44%)
Taking everything into account, CPRX scores 8 out of 10 in our fundamental rating. CPRX was compared to 525 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making CPRX a very profitable company, without any liquidiy or solvency issues. CPRX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make CPRX a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
- CPRX had positive earnings in the past year.
- CPRX had a positive operating cash flow in the past year.
- CPRX had positive earnings in each of the past 5 years.
- In the past 5 years CPRX always reported a positive cash flow from operatings.
1.2 Ratios
- With an excellent Return On Assets value of 20.69%, CPRX belongs to the best of the industry, outperforming 97.14% of the companies in the same industry.
- CPRX has a better Return On Equity (23.65%) than 96.76% of its industry peers.
- CPRX's Return On Invested Capital of 21.23% is amongst the best of the industry. CPRX outperforms 97.90% of its industry peers.
- CPRX had an Average Return On Invested Capital over the past 3 years of 20.37%. This is above the industry average of 18.07%.
- The 3 year average ROIC (20.37%) for CPRX is below the current ROIC(21.23%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROIC | 21.23% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
1.3 Margins
- CPRX's Profit Margin of 37.64% is amongst the best of the industry. CPRX outperforms 96.76% of its industry peers.
- In the last couple of years the Profit Margin of CPRX has remained more or less at the same level.
- CPRX has a better Operating Margin (44.78%) than 99.43% of its industry peers.
- In the last couple of years the Operating Margin of CPRX has grown nicely.
- With an excellent Gross Margin value of 85.68%, CPRX belongs to the best of the industry, outperforming 88.38% of the companies in the same industry.
- In the last couple of years the Gross Margin of CPRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% |
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CPRX is creating value.
- Compared to 1 year ago, CPRX has more shares outstanding
- CPRX has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 15.53 indicates that CPRX is not in any danger for bankruptcy at the moment.
- The Altman-Z score of CPRX (15.53) is better than 85.90% of its industry peers.
- CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.53 |
ROIC/WACC2.39
WACC8.88%
2.3 Liquidity
- A Current Ratio of 6.62 indicates that CPRX has no problem at all paying its short term obligations.
- The Current ratio of CPRX (6.62) is better than 67.62% of its industry peers.
- CPRX has a Quick Ratio of 6.40. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
- CPRX has a better Quick ratio (6.40) than 66.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 45.76% over the past year.
- Measured over the past years, CPRX shows a very strong growth in Earnings Per Share. The EPS has been growing by 34.29% on average per year.
- The Revenue has grown by 25.56% in the past year. This is a very strong growth!
- Measured over the past years, CPRX shows a very strong growth in Revenue. The Revenue has been growing by 36.89% on average per year.
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
3.2 Future
- The Earnings Per Share is expected to grow by 26.80% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 11.21% on average over the next years. This is quite good.
EPS Next Y24.97%
EPS Next 2Y18.55%
EPS Next 3Y12.53%
EPS Next 5Y26.8%
Revenue Next Year19.37%
Revenue Next 2Y13.05%
Revenue Next 3Y11.23%
Revenue Next 5Y11.21%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- CPRX is valuated correctly with a Price/Earnings ratio of 13.20.
- CPRX's Price/Earnings ratio is rather cheap when compared to the industry. CPRX is cheaper than 96.95% of the companies in the same industry.
- CPRX is valuated cheaply when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 12.33, the valuation of CPRX can be described as correct.
- Based on the Price/Forward Earnings ratio, CPRX is valued cheaper than 96.95% of the companies in the same industry.
- CPRX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.29.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.2 | ||
| Fwd PE | 12.33 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, CPRX is valued cheaper than 98.48% of the companies in the same industry.
- CPRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CPRX is cheaper than 97.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.89 | ||
| EV/EBITDA | 7.08 |
4.3 Compensation for Growth
- CPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- CPRX has an outstanding profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as CPRX's earnings are expected to grow with 12.53% in the coming years.
PEG (NY)0.53
PEG (5Y)0.38
EPS Next 2Y18.55%
EPS Next 3Y12.53%
5. Dividend
5.1 Amount
- CPRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
22.7
-0.26 (-1.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners86.97%
Inst Owner Change-0.58%
Ins Owners5.48%
Ins Owner Change2.85%
Market Cap2.79B
Revenue(TTM)578.20M
Net Income(TTM)217.63M
Analysts88.57
Price Target35.12 (54.71%)
Short Float %6.84%
Short Ratio6.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.08%
Min EPS beat(2)4.13%
Max EPS beat(2)24.03%
EPS beat(4)4
Avg EPS beat(4)21.33%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)7
Avg EPS beat(8)16.56%
EPS beat(12)10
Avg EPS beat(12)13.3%
EPS beat(16)12
Avg EPS beat(16)8.79%
Revenue beat(2)2
Avg Revenue beat(2)4.27%
Min Revenue beat(2)2.19%
Max Revenue beat(2)6.34%
Revenue beat(4)4
Avg Revenue beat(4)4.39%
Min Revenue beat(4)2.19%
Max Revenue beat(4)6.34%
Revenue beat(8)7
Avg Revenue beat(8)3.51%
Revenue beat(12)11
Avg Revenue beat(12)3.34%
Revenue beat(16)13
Avg Revenue beat(16)2.97%
PT rev (1m)-0.21%
PT rev (3m)1.26%
EPS NQ rev (1m)7.95%
EPS NQ rev (3m)23.15%
EPS NY rev (1m)1.71%
EPS NY rev (3m)10.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.2 | ||
| Fwd PE | 12.33 | ||
| P/S | 4.83 | ||
| P/FCF | 11.89 | ||
| P/OCF | 11.88 | ||
| P/B | 3.03 | ||
| P/tB | 3.52 | ||
| EV/EBITDA | 7.08 |
EPS(TTM)1.72
EY7.58%
EPS(NY)1.84
Fwd EY8.11%
FCF(TTM)1.91
FCFY8.41%
OCF(TTM)1.91
OCFY8.41%
SpS4.7
BVpS7.49
TBVpS6.44
PEG (NY)0.53
PEG (5Y)0.38
Graham Number17.02
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROCE | 28.06% | ||
| ROIC | 21.23% | ||
| ROICexc | 84.1% | ||
| ROICexgc | 187.79% | ||
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% | ||
| FCFM | 40.59% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexgc growth 3Y8.72%
ROICexgc growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 0.31% | ||
| Cap/Sales | 0.02% | ||
| Interest Coverage | 593.88 | ||
| Cash Conversion | 79.12% | ||
| Profit Quality | 107.83% | ||
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 | ||
| Altman-Z | 15.53 |
F-Score6
WACC8.88%
ROIC/WACC2.39
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
EPS Next Y24.97%
EPS Next 2Y18.55%
EPS Next 3Y12.53%
EPS Next 5Y26.8%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
Revenue Next Year19.37%
Revenue Next 2Y13.05%
Revenue Next 3Y11.23%
Revenue Next 5Y11.21%
EBIT growth 1Y48.97%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year76.08%
EBIT Next 3Y25.59%
EBIT Next 5YN/A
FCF growth 1Y83.47%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y83.42%
OCF growth 3Y58.35%
OCF growth 5Y47.28%
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a fundamental rating of 8 / 10 to CPRX.
What is the valuation status for CPRX stock?
ChartMill assigns a valuation rating of 8 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.
Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 9 / 10.
What is the expected EPS growth for CATALYST PHARMACEUTICALS INC (CPRX) stock?
The Earnings per Share (EPS) of CATALYST PHARMACEUTICALS INC (CPRX) is expected to grow by 24.97% in the next year.